Literature DB >> 15176758

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.

Jeffrey W Swanson1, Marvin S Swartz, Eric B Elbogen.   

Abstract

This study prospectively compared the effectiveness of atypical antipsychotic medications to that of conventional neuroleptics in reducing violent behavior among patients with schizophrenia under "usual care" conditions in the community. Participants (n = 229) were adults with schizophrenia spectrum disorders receiving inpatient or outpatient services in public sector mental health systems in North Carolina. Subjects were followed for 2 years in an observational study using multiple methods of data collection at 6-month intervals to assess treatment, sociodemographic characteristics, clinical features, and violence outcomes. Treatment with atypical antipsychotic medications (clozapine, risperidone, or olanzapine) was found to significantly reduce the risk of violent behavior, whereas treatment with conventional neuroleptics did not have this same beneficial effect. A cumulative effect on reduced violence was attributable to consistent compliance with atypical antipsychotic medications over a 2-year period. Concurrent reductions in psychotic symptoms, substance abuse, and adverse medication side effects were found to mediate the association between adherence with atypicals and lower violence risk. Treatment with atypical antipsychotic medications should be considered as an important component of violence risk management for schizophrenia patients at risk for violent behavior.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176758     DOI: 10.1093/oxfordjournals.schbul.a007065

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  40 in total

1.  An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital.

Authors:  Nina Baruch; Mrigendra Das; Amit Sharda; Amlan Basu; Tom Bajorek; Callum C Ross; Samrat Sengupta; Fintan Larkin; Susan Young
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Managing pathologic aggression in people with psychotic disorders.

Authors:  Dominique Bourget; Alain Labelle
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

Review 3.  Neuroimaging correlates of aggression in schizophrenia: an update.

Authors:  Matthew J Hoptman; Daniel Antonius
Journal:  Curr Opin Psychiatry       Date:  2011-03       Impact factor: 4.741

4.  The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Authors:  Robert R Conley; Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Bruce J Kinon
Journal:  Schizophr Res       Date:  2006-11-15       Impact factor: 4.939

Review 5.  Perpetration of violence, violent victimization, and severe mental illness: balancing public health concerns.

Authors:  Jeanne Y Choe; Linda A Teplin; Karen M Abram
Journal:  Psychiatr Serv       Date:  2008-02       Impact factor: 3.084

6.  Violence and schizophrenia.

Authors:  Heidi J Wehring; William T Carpenter
Journal:  Schizophr Bull       Date:  2011-09       Impact factor: 9.306

7.  Community violence perpetration and victimization among adults with mental illnesses.

Authors:  Sarah L Desmarais; Richard A Van Dorn; Kiersten L Johnson; Kevin J Grimm; Kevin S Douglas; Marvin S Swartz
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

8.  The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18.

Authors:  Richard A Van Dorn; Sarah L Desmarais; Kevin J Grimm; Stephen J Tueller; Kiersten L Johnson; Brian G Sellers; Marvin S Swartz
Journal:  Psychiatry Res       Date:  2016-08-09       Impact factor: 3.222

9.  Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

Authors:  J Volavka; R A Van Dorn; L Citrome; R S Kahn; W W Fleischhacker; P Czobor
Journal:  Eur Psychiatry       Date:  2015-12-04       Impact factor: 5.361

10.  Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.